Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-03-17FDA Approved: LACOSAMIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved lacosamide as an original application (ANDA) for Amneal Pharmaceuticals of New York LLC, making a generic lacosamide available …
-
CLINICAL_TRIALS research · 2022-03-09Clinical Trial Update: Role of the Gut Microbiota in Pediatric Epilepsy [Phase 4]
Phase 4 clinical trial exploring how gut microbiota affects pediatric epilepsy in drug-resistant cases.
-
FDA approval · 2022-03-08FDA Approved: LEVETIRACETAM — Supplemental Application (Mylan Institutional LLC)
FDA approves a supplemental application for levetiracetam from Mylan Institutional LLC.
-
FDA approval · 2022-03-03FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for DILANTIN-125 (phenytoin) from Viatris Specialty LLC, adding a supplemental dosage strength/f…
-
FDA approval · 2022-02-22FDA Approved: ETHOSUXIMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ethosuximide from Chartwell RX, LLC, indicating regulatory approval of a change to the approved …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-02-16FDA Approved: ETHOSUXIMIDE — Supplemental Application (Bionpharma Inc.)
The FDA approved a supplemental application for Ethosuximide from Bionpharma Inc., indicating regulatory changes were approved for this prod…
-
FDA approval · 2022-02-04FDA Approved: TOPIRAMATE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for Topiramate from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2022-02-04FDA Approved: VALTOCO — Supplemental Application (Neurelis, Inc)
The FDA approved a supplemental application for VALTOCO (diazepam) by Neurelis, Inc.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes [Phase 3]
Open-label extension study of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes completed; results pos…
-
CLINICAL_TRIALS trial_result · 2022-01-31Clinical Trial Update: Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects [Phase 3]
A Phase 3 repeat-dose safety study in epilepsy subjects has completed, with results posted in 2022.
-
FDA approval · 2022-01-19FDA Approved: VIGABATRIN — Original Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved the original application for vigabatrin by Zydus Pharmaceuticals (USA) Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: An Open-Label Study to Determine Safety , Tolerability, and Efficacy of Oral Lacosamide in Children With Epilepsy [Phase 2]
Phase 2 open-label trial assessing safety, tolerability, and efficacy of oral lacosamide in children with epilepsy completed.
-
CLINICAL_TRIALS trial_result · 2022-01-18Clinical Trial Update: EMR Outcomes: Anxiety and Depression in Epilepsy [NA]
Clinical trial update reporting outcomes on anxiety and depression related to epilepsy, with completed status and posted results.
-
FDA approval · 2022-01-13FDA Approved: TOPAMAX — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Topamax (topiramate) submitted by Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy [Phase 4]
A Phase 4 clinical trial evaluating a probiotic in adult patients with drug-resistant epilepsy has been completed.
-
FDA approval · 2022-01-11FDA Approved: OXCARBAZEPINE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original ANDA for oxcarbazepine, a generic anticonvulsant indicated for partial seizures.
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Fycompa Titration Intervals and Effects on Retention Rate [Phase 4]
Phase 4 trial evaluating Fycompa (perampanel) titration intervals and their impact on retention rate in epilepsy.
-
FDA approval · 2021-12-08FDA Approved: LAMOTRIGINE — Original Application (Yiling Pharmaceutical, Inc.)
The FDA approved Yiling Pharmaceutical's generic lamotrigine extended-release via Original Application (ANDA), enabling a generic lamotrigin…
-
FDA approval · 2021-12-03FDA Approved: CLOBAZAM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for CLOBAZAM from Lupin Pharmaceuticals, Inc. to support an updated or expanded use of the product.
-
FDA approval · 2021-12-01FDA Approved: CARBATROL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for CARBATROL (carbamazepine) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2021-11-26Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy [Phase 2]
Phase 2 trial evaluating pharmacokinetics, safety, and tolerability of intravenous brivaracetam in pediatric patients aged 1 month to under …
-
FDA approval · 2021-11-16FDA Approved: LEVETIRACETAM — Supplemental Application (Solco healthcare U.S., LLC)
FDA approved a supplemental application for levetiracetam from Solco Healthcare U.S., LLC, enabling a generic version under ANDA203468.
-
FDA approval · 2021-11-16FDA Approved: TIAGABINE HYDROCHLORIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved the original ANDA for tiagabine hydrochloride from Novadoz Pharmaceuticals LLC, granting a generic version for the treatment of…
-
FDA approval · 2021-11-12FDA Approved: DIAZEPAM — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Diazepam from Hikma Pharmaceuticals USA Inc. under an ANDA, reflecting a regulatory action on th…
-
FDA approval · 2021-11-09FDA Approved: LAMOTRIGINE EXTENDED RELEASE — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Lamotrigine Extended Release from Par Health USA, LLC, approving a generic extended-release …